Amylyx Pharmaceuticals, Inc./$AMLX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.

Ticker

$AMLX
Sector
Primary listing

Employees

123

AMLX Metrics

BasicAdvanced
$1.5B
-
-$2.41
-0.45
-

Bulls say / Bears say

A U.S. FDA advisory committee voted 7-to-2 in favor of AMX0035 for ALS on September 8, resulting in a 70% jump in Amylyx shares and highlighting strong regulatory support for its lead therapy (Reuters)
On September 30, the FDA approved Relyvrio and Amylyx set its first-year price at $158,000, pointing to clear reimbursement prospects and a strong revenue outlook in the ALS market (Reuters)
Amylyx widened its pipeline by advancing avexitide for post-bariatric hypoglycemia after acquiring it from Eiger BioPharmaceuticals in 2024, expanding beyond neurodegenerative therapies (Reuters)
AMX0035 failed to show efficacy in a mid-stage trial for progressive supranuclear palsy, leading Amylyx to stop both the PSP program and its open-label extension, leaving a significant gap in the pipeline (Reuters)
In August, Amylyx announced it voluntarily withdrew Relyvrio from U.S. and Canadian markets in 2024 after a failed late-stage ALS trial, emphasizing past regulatory and efficacy setbacks that have strained commercial prospects (Reuters)
Amylyx’s late-stage pipeline is now centered on just two products—AMX0035 for Wolfram syndrome and avexitide for post-bariatric hypoglycemia—upping development risks due to limited diversification (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AMLX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs